CN113164456A - 使用四环素化合物治疗分枝杆菌感染的方法 - Google Patents

使用四环素化合物治疗分枝杆菌感染的方法 Download PDF

Info

Publication number
CN113164456A
CN113164456A CN201980072989.8A CN201980072989A CN113164456A CN 113164456 A CN113164456 A CN 113164456A CN 201980072989 A CN201980072989 A CN 201980072989A CN 113164456 A CN113164456 A CN 113164456A
Authority
CN
China
Prior art keywords
alkyl
subject
alkynyl
alkenyl
mycobacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980072989.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·H·西纳蒙
M·P·德拉珀
J·N·斯蒂恩伯根
S·K·塔纳卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paratek Pharmaceuticals Inc
US Department of Veterans Affairs
Original Assignee
Paratek Pharmaceuticals Inc
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharmaceuticals Inc, US Department of Veterans Affairs filed Critical Paratek Pharmaceuticals Inc
Publication of CN113164456A publication Critical patent/CN113164456A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201980072989.8A 2018-09-04 2019-09-03 使用四环素化合物治疗分枝杆菌感染的方法 Pending CN113164456A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862726738P 2018-09-04 2018-09-04
US62/726738 2018-09-04
US201862731410P 2018-09-14 2018-09-14
US62/731410 2018-09-14
US201862746039P 2018-10-16 2018-10-16
US62/746039 2018-10-16
US201862760131P 2018-11-13 2018-11-13
US62/760131 2018-11-13
PCT/US2019/049368 WO2020051151A1 (en) 2018-09-04 2019-09-03 Methods of treating mycobacterial infections using tetracycline compounds

Publications (1)

Publication Number Publication Date
CN113164456A true CN113164456A (zh) 2021-07-23

Family

ID=69722600

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980072989.8A Pending CN113164456A (zh) 2018-09-04 2019-09-03 使用四环素化合物治疗分枝杆菌感染的方法

Country Status (13)

Country Link
US (2) US12161655B2 (https=)
EP (1) EP3846805A4 (https=)
JP (2) JP7466544B2 (https=)
KR (2) KR20260036400A (https=)
CN (1) CN113164456A (https=)
AU (2) AU2019335203B2 (https=)
BR (1) BR112021004057A2 (https=)
CA (1) CA3111447A1 (https=)
MA (1) MA53564A (https=)
MX (2) MX2021002503A (https=)
PH (1) PH12021550452A1 (https=)
SG (1) SG11202102149SA (https=)
WO (1) WO2020051151A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7840880B2 (ja) * 2020-06-11 2026-04-06 パラテック ファーマシューティカルズ，インコーポレイテッド オマダサイクリンの結晶形態、その合成方法及びその使用方法
TW202237116A (zh) * 2020-12-02 2022-10-01 日商塩野義製藥股份有限公司 以組合細胞色素bc1抑制劑與克拉黴素或阿奇黴素為特徵之用於治療分枝桿菌感染之藥物
JP2024511419A (ja) * 2021-03-24 2024-03-13 インスメッド インコーポレイテッド 非結核性抗酸菌肺疾患を治療するための併用療法
WO2025221846A1 (en) * 2024-04-18 2025-10-23 St. Jude Children's Research Hospital, Inc. Compositions and methods for treating non-tuberculosis mycobacteria infections

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1471509A (zh) * 2000-07-07 2004-01-28 ���Ĵ���ѧ 9-取代的二甲胺四环素化合物
CN102046177A (zh) * 2008-03-28 2011-05-04 帕拉特克药品公司 四环素化合物的口服和注射制剂
US20170319603A1 (en) * 2016-03-24 2017-11-09 Paratek Pharmaceuticals, Inc. Methods for treating and preventing c. difficile infection
US20170333455A1 (en) * 2016-05-02 2017-11-23 Paratek Pharmaceuticals, Inc. 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment
US20180016225A1 (en) * 2001-07-13 2018-01-18 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
US20180055859A1 (en) * 2016-08-03 2018-03-01 Paratek Pharmaceuticals, Inc. 9-aminomethyl minocycline compounds and uses thereof
WO2018051102A1 (en) * 2016-09-15 2018-03-22 Antibiotx A/S Combinations comprising dibromopropamidine or diminazene and a tetracycline anti-bacterial agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553828B2 (en) 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
EP2311451A1 (en) 2002-03-08 2011-04-20 Paratek Pharmaceuticals, Inc. Amino-methyl substituted tetracycline compounds
TWI680117B (zh) 2008-05-19 2019-12-21 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
KR101732084B1 (ko) 2011-07-26 2017-05-02 케이비피 바이오사이언시즈 씨오., 엘티디. 9-아미노메틸 치환된 테트라사이클린 화합물
JP2015527403A (ja) 2012-09-11 2015-09-17 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖプロテアーゼ阻害剤

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1471509A (zh) * 2000-07-07 2004-01-28 ���Ĵ���ѧ 9-取代的二甲胺四环素化合物
US20180016225A1 (en) * 2001-07-13 2018-01-18 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
CN102046177A (zh) * 2008-03-28 2011-05-04 帕拉特克药品公司 四环素化合物的口服和注射制剂
US20170319603A1 (en) * 2016-03-24 2017-11-09 Paratek Pharmaceuticals, Inc. Methods for treating and preventing c. difficile infection
US20170333455A1 (en) * 2016-05-02 2017-11-23 Paratek Pharmaceuticals, Inc. 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment
US20180055859A1 (en) * 2016-08-03 2018-03-01 Paratek Pharmaceuticals, Inc. 9-aminomethyl minocycline compounds and uses thereof
WO2018051102A1 (en) * 2016-09-15 2018-03-22 Antibiotx A/S Combinations comprising dibromopropamidine or diminazene and a tetracycline anti-bacterial agent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CYNAMON M等: "In Vitro Activity of TP-271 against Mycobacterium abscessus, Mycobacterium fortuitum, and Nocardia Species", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 56, no. 7, pages 3986 - 3988, XP055692078, DOI: 10.1128/AAC.00743-12 *
WALLACE R J等: "Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 46, no. 10, pages 3164 - 3167, XP055942573, DOI: 10.1128/AAC.46.10.3164-3167.2002 *

Also Published As

Publication number Publication date
JP2021536504A (ja) 2021-12-27
US20210346408A1 (en) 2021-11-11
EP3846805A1 (en) 2021-07-14
US20250332178A1 (en) 2025-10-30
US12161655B2 (en) 2024-12-10
MX2021002503A (es) 2021-06-15
AU2025234215A1 (en) 2025-10-16
KR20260036400A (ko) 2026-03-16
AU2019335203B2 (en) 2025-06-19
KR102933150B1 (ko) 2026-03-03
BR112021004057A2 (pt) 2021-05-25
EP3846805A4 (en) 2022-08-24
MA53564A (fr) 2021-07-14
WO2020051151A1 (en) 2020-03-12
SG11202102149SA (en) 2021-04-29
PH12021550452A1 (en) 2021-12-06
MX2024008671A (es) 2024-07-23
JP2024084794A (ja) 2024-06-25
CA3111447A1 (en) 2020-03-12
KR20210090160A (ko) 2021-07-19
AU2019335203A1 (en) 2021-05-06
JP7466544B2 (ja) 2024-04-12

Similar Documents

Publication Publication Date Title
JP2024084794A (ja) テトラサイクリン化合物を使用してマイコバクテリア感染症を処置する方法
US20210308153A1 (en) Halogenated salicylanilides for treating clostridium infections
JP5469511B2 (ja) 微生物の院内感染症の治療用医薬の製造におけるタウロリジンまたはタウラルタムのような抗微生物薬剤の使用
JP5782615B2 (ja) オリタバンシンの単回用量を用いる治療の方法
Galgiani et al. Bacteroides fragilis endocarditis, bacteremia and other infections treated with oral or intravenous metronidazole
US20100152101A1 (en) Triazol compounds for treating biofilm formation
US10758529B2 (en) Pharmaceutical compositions containing azaquinone for inhibiting clostridium difficile activity
WO2023246841A1 (en) Methods and uses of boron compounds in the treatment of nontuberculous mycobacterium infections and pharmaceutical compositions for treatment of same
ES2690725T3 (es) Composiciones que comprenden cefepima y tazobactam
PT1663233E (pt) Utilização de tigeciclina isolada ou em combinação com rifampina para o tratamento de osteomielite e/ou artrite séptica
Karak et al. Antibacterial potential of an antispasmodic drug dicyclomine hydrochloride
RU2831120C2 (ru) Способы лечения микобактериальных инфекций с применением тетрациклиновых соединений
Amangeldykyzy et al. The effect of a combined choline salicylate and cetalkonium chloride gel on particular strains of Pseudomonas aeruginosa, Staphylococcus spp. and Streptococcus spp.
KR101401869B1 (ko) 에스트로젠의 마이코박테리아 균주 감염 억제용 용도
Matsumoto et al. Laboratory Evaluation of Cefmenoxime: a New Cephalosporin: In vitro and in vivo Antibacterial Activities and Pharmacokinetic Properties
WO2024175768A1 (en) Combination of fabi inhibitor and antibiotic agent
Gismondo et al. Impact of cefetamet-pivoxil on intestinal microflora: in vivo study
Steckelberg et al. In Vitro and In Vivo Evaluations of the
HK1146223A (en) Triazol compounds for treating biofilm formation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination